Document Detail

[Brain metastases of non small cell lung cancers: systemic treatments].
MedLine Citation:
PMID:  23376611     Owner:  NLM     Status:  MEDLINE    
Chemotherapy, as all systemic treatments, is generally effective in brain metastases because the brain blood barrier (BBB) does not affect treatment's diffusion. Platinum-based chemotherapy provides response rates ranging from 23 to 50% for brain metastases. Anti-EGFR therapies are effective mostly when a somatic EGFR activating mutation is detected, or in selected population (adenocarcinoma, Asian population, never-smokers and women): response rate ranges from 38 to 69.6%. Bevacizumab is now allowed for non-small cell lung cancer (NSCLC) patients with brain metastases and non-squamous histology. The presence of untreated brain metastases may not influence its efficacy combined with paclitaxel-carboplatin. The best sequence for multimodality management of brain metastases has to be established but upfront systemic treatments in patients with asymptomatic brain metastases is a valid option.
Marie Chaubet-Houdu; Benjamin Besse
Publication Detail:
Type:  English Abstract; Journal Article; Review    
Journal Detail:
Title:  Bulletin du cancer     Volume:  100     ISSN:  1769-6917     ISO Abbreviation:  Bull Cancer     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-02-08     Completed Date:  2013-03-25     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0072416     Medline TA:  Bull Cancer     Country:  France    
Other Details:
Languages:  fre     Pagination:  95-8     Citation Subset:  IM    
Institut Gustave-Roussy, Département de Médecine Oncologique, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
Vernacular Title:
Métastases cérébrales des cancers bronchiques non à petites cellules : traitement systémique.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Brain Neoplasms / drug therapy*,  secondary*
Carcinoma, Non-Small-Cell Lung / drug therapy*,  secondary*
Cisplatin / therapeutic use
Lung Neoplasms*
Pyrazoles / therapeutic use
Pyridines / therapeutic use
Quinazolines / therapeutic use
Receptor, Epidermal Growth Factor / antagonists & inhibitors
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 0/Pyrazoles; 0/Pyridines; 0/Quinazolines; 15663-27-1/Cisplatin; 2S9ZZM9Q9V/bevacizumab; 53AH36668S/crizotinib; EC, Epidermal Growth Factor; S65743JHBS/gefitinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  FGF signalling through Fgfr2 isoform IIIb regulates adrenal cortex development.
Next Document:  Zebrafish and steroids: what do we know and what do we need to know?